Akodad Mariama, Blanke Philipp, Nestelberger Thomas, Alosail Abdulmajeed, Chatfield Andrew G, Chuang Ming-Yu A, Leipsic Jonathon A, Tzimas Georgios, Lounes Youcef, Meier David, Sathananthan Janarthanan, Wood David A, Webb John G
Centres for Heart Valve Innovation and for Cardiovascular Innovation, St. Paul's and Vancouver General Hospitals, Vancouver, British Columbia, Canada; Division of Cardiology, University of British Columbia & St. Paul's Hospital, Vancouver, British Columbia, Canada; Cardiovascular Translational Laboratory, Centre for Heart Lung Innovation, University of British Columbia & St. Paul's Hospital, Vancouver, British Columbia, Canada.
Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
JACC Cardiovasc Interv. 2022 Dec 12;15(23):2387-2395. doi: 10.1016/j.jcin.2022.10.035. Epub 2022 Nov 16.
The cusp-overlap (CO) technique has recently been advocated and is being increasingly adopted for self-expandable transcatheter heart valve (THV) implantation.
The aim of this study was to evaluate the feasibility, implantation depth, and outcomes of the CO technique for the balloon-expandable SAPIEN 3 THV.
The CO technique was used in consecutive patients undergoing balloon-expandable THV implantation at one center between April 2021 and March 2022. Optimal fluoroscopic angles were determined from preprocedural computed tomography and confirmed on predeployment angiography. The THV radiolucent line was positioned 2 to 4 mm below the noncoronary cusp in the CO view, and positioning was confirmed in the 3-cusp view. Postdeployment THV implantation depth was assessed in both views. One-month outcomes were assessed using Valve Academic Research Consortium 3 criteria.
Among 137 patients eligible for the CO technique, the CO view was not used because of unfavorable ergonomics in 27 patients (26.5%) and hemodynamic instability in 8 patients (7.8%). Among 102 patients, the mean age was 81.1 ± 6.6 years, the mean Society of Thoracic Surgeons score was 3.3% ± 2.2%, and 64.7% were men. The mean measured THV implantation depth was 3.0 ± 1.4 mm in the CO view and 2.5 ± 1.4 mm in the 3-cusp view. At 1-month follow-up, 1 patient (1.0%) had died, 1 (1.0%) had had a stroke, and 7 (6.8%) had undergone permanent pacemaker implantation.
The CO technique is feasible and safe and may facilitate more accurate balloon-expandable THV positioning, especially when deep implantation needs to be avoided. Further studies are required to explore potential reduction in atrioventricular conduction block, pacemakers, or paravalvular regurgitation.
瓣叶重叠(CO)技术最近受到提倡,并且在自膨胀经导管心脏瓣膜(THV)植入中越来越多地被采用。
本研究的目的是评估CO技术用于球囊扩张式SAPIEN 3 THV的可行性、植入深度和结果。
2021年4月至2022年3月期间,在一个中心对连续接受球囊扩张式THV植入的患者使用CO技术。术前计算机断层扫描确定最佳透视角度,并在预释放血管造影术中得到确认。在CO视图中,将THV的透射线置于无冠瓣叶下方2至4毫米处,并在三尖瓣视图中确认定位。在两个视图中评估释放后THV的植入深度。使用瓣膜学术研究联盟3标准评估1个月的结果。
在137例适合CO技术的患者中,27例(26.5%)因人体工程学不佳、8例(7.8%)因血流动力学不稳定未使用CO视图。在102例患者中,平均年龄为81.1±6.6岁,平均胸外科医师协会评分为3.3%±2.2%,男性占64.7%。在CO视图中,测得的THV平均植入深度为3.0±1.4毫米,在三尖瓣视图中为2.5±1.4毫米。在1个月的随访中,1例患者(1.0%)死亡,1例(1.0%)发生中风,7例(6.8%)接受了永久性起搏器植入。
CO技术可行且安全,可能有助于更准确地定位球囊扩张式THV,特别是在需要避免深度植入时。需要进一步研究以探索房室传导阻滞、起搏器或瓣周反流潜在减少的情况。